Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CKD-519 in Healthy Volunteers
NCT02156544Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rocacetrapib in dyslipidemia (5 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at 168 hours, Area Under the Curve to Last Measurable Concentration at 168 hours and 5 more. Started Jun 2014; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02156544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156544.